Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
CANTON, Mass., May 03, 2017 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2017 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (888)698-6931 (U.S.) or (805)905-2993 (International). An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact: Alexandra Dasalla [email protected]
